Analysts’ Weekly Ratings Changes for Health Catalyst (HCAT)

A number of firms have modified their ratings and price targets on shares of Health Catalyst (NASDAQ: HCAT) recently:

• 3/27/2026 – Health Catalyst had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 3/18/2026 – Health Catalyst had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $1.00 price target on the stock, down from $5.00.
• 3/13/2026 – Health Catalyst had its price target lowered by Cantor Fitzgerald from $4.00 to $3.00. They now have a “neutral” rating on the stock.
• 3/13/2026 – Health Catalyst was given a new $3.00 price target by Raymond James Financial, Inc..
• 3/13/2026 – Health Catalyst had its price target lowered by Canaccord Genuity Group Inc. from $5.00 to $2.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Health Catalyst had its price target lowered by Citigroup Inc. from $2.75 to $1.75. They now have a “neutral” rating on the stock.
• 3/13/2026 – Health Catalyst had its price target lowered by Stephens from $3.50 to $2.00. They now have an “equal weight” rating on the stock.
• 3/13/2026 – Health Catalyst had its price target lowered by Stifel Nicolaus from $3.75 to $2.00. They now have a “hold” rating on the stock.

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.